Dr. Benjamin M. Solomon

About Benjamin M. Solomon

Education:

• Earned an MD from the University of Nebraska Medical Center.

Experience:

• Currently a Medical Oncologist at Avera Cancer Institute.
• Serves as an Associate Professor of Medicine at USD Sanford School of Medicine, Sioux Falls, South Dakota.
• Holds administrative positions including Medical Information Officer and Oncology Clinical Research Officer at Avera.
• Specializes in the diagnosis and management of solid tumors, particularly in head/neck and thoracic malignancies.
• Research focuses on clinical trials, precision oncology, and cellular therapy for lung and head/neck cancers.

Area of expertise

Affiliated Hospitals

Avera Cancer Institute

Avera Cancer Institute-Aberdeen

Clinical Trials Benjamin M. Solomon is currently running

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.

Recruiting2 awards Phase 34 criteria

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.

Recruiting1 award Phase 231 criteria

More about Benjamin M. Solomon

Other Doctors you might be interested in

Frequently asked questions